Equities Analysts Issue Forecasts for SGMT Q2 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for shares of Sagimet Biosciences in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q3 2026 earnings at ($0.26) EPS and Q4 2026 earnings at ($0.30) EPS.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06.

Other equities research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Tuesday, April 21st. Barclays assumed coverage on Sagimet Biosciences in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price target for the company. Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Wall Street Zen raised Sagimet Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Canaccord Genuity Group raised their price objective on Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Sagimet Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $28.63.

Sagimet Biosciences Trading Down 0.7%

Shares of NASDAQ SGMT opened at $7.60 on Thursday. Sagimet Biosciences has a one year low of $3.08 and a one year high of $11.41. The firm has a market capitalization of $247.61 million, a PE ratio of -5.67 and a beta of 3.60. The business has a 50-day moving average price of $5.97 and a two-hundred day moving average price of $6.29.

Institutional Trading of Sagimet Biosciences

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in Sagimet Biosciences by 0.6% in the 2nd quarter. Geode Capital Management LLC now owns 265,324 shares of the company’s stock valued at $2,023,000 after buying an additional 1,600 shares in the last quarter. Landscape Capital Management L.L.C. raised its position in Sagimet Biosciences by 14.1% in the 4th quarter. Landscape Capital Management L.L.C. now owns 25,901 shares of the company’s stock valued at $153,000 after purchasing an additional 3,198 shares during the last quarter. HighTower Advisors LLC raised its position in Sagimet Biosciences by 10.1% in the 4th quarter. HighTower Advisors LLC now owns 37,189 shares of the company’s stock valued at $220,000 after purchasing an additional 3,408 shares during the last quarter. American Century Companies Inc. raised its position in Sagimet Biosciences by 8.9% in the 2nd quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after purchasing an additional 3,454 shares during the last quarter. Finally, Royal Bank of Canada raised its position in Sagimet Biosciences by 819.2% in the 4th quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares during the last quarter. Institutional investors and hedge funds own 87.86% of the company’s stock.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.